Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hormones of the Pituitary Gland01:27

Hormones of the Pituitary Gland

The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The changing epidemiology of <i>Candida</i> species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.

Expert review of anti-infective therapy·2025
Same author

Correction: Tegileridine: First Approval.

Drugs·2024
Same author

Ivonescimab: First Approval.

Drugs·2024
Same author

Tarlatamab: First Approval.

Drugs·2024
Same author

Tovorafenib: First Approval.

Drugs·2024
Same author

Zevorcabtagene Autoleucel: First Approval.

Molecular diagnosis & therapy·2024
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Jul 3, 2026

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

Lutropin alfa.

Sohita Dhillon1, Gillian M Keating

  • 1Wolters Kluwer Health | Adis, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 17, 2008
PubMed
Summary
This summary is machine-generated.

Recombinant luteinizing hormone (LH), lutropin alfa, effectively stimulates follicular development in women with hypogonadotropic hypogonadism. Supplementation with lutropin alfa alongside follitropin alfa improved outcomes in specific patient groups.

More Related Videos

Frequent Tail-tip Blood Sampling in Mice for the Assessment of Pulsatile Luteinizing Hormone Secretion
05:58

Frequent Tail-tip Blood Sampling in Mice for the Assessment of Pulsatile Luteinizing Hormone Secretion

Published on: July 4, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

Frequent Tail-tip Blood Sampling in Mice for the Assessment of Pulsatile Luteinizing Hormone Secretion
05:58

Frequent Tail-tip Blood Sampling in Mice for the Assessment of Pulsatile Luteinizing Hormone Secretion

Published on: July 4, 2018

Area of Science:

  • Reproductive endocrinology and infertility treatments.

Background:

  • Lutropin alfa is a novel recombinant human luteinizing hormone (LH) designed to enhance follicular development.
  • Women with hypogonadotropic hypogonadism and profound LH deficiency often require LH supplementation for effective ovulation induction.

Purpose of the Study:

  • To evaluate the efficacy and safety of lutropin alfa in stimulating follicular development.
  • To determine optimal dosing of lutropin alfa in combination with follitropin alfa for women with hypogonadotropic hypogonadism and profound LH deficiency.

Main Methods:

  • Dose-finding studies assessed the impact of varying subcutaneous lutropin alfa doses (0-225 IU/day) plus follitropin alfa on follicular development rates.
  • A double-blind, randomized study compared lutropin alfa (75 IU/day) plus follitropin alfa against placebo plus follitropin alfa in women with hypogonadotropic hypogonadism and profound LH deficiency.

Main Results:

  • A significant, dose-dependent increase in optimal follicular development was observed with lutropin alfa plus follitropin alfa in women with profound LH deficiency.
  • Lutropin alfa (75 IU/day) plus follitropin alfa significantly improved optimal follicular development rates compared to placebo plus follitropin alfa in this population.
  • Potential benefits were noted in specific subgroups of normogonadotropic women, though one study in older women showed no added advantage.

Conclusions:

  • Lutropin alfa, when combined with follitropin alfa, is effective in improving follicular development in women with hypogonadotropic hypogonadism and profound LH deficiency.
  • The combination therapy demonstrates a favorable safety profile, with most adverse events being mild to moderate.
  • Further research may clarify the role of lutropin alfa in specific normogonadotropic subgroups.